Inflarx NV logo

IFRX - Inflarx NV Share Price

$3.7 0.0  0.0%

Last Trade - 16/04/21

Small Cap
Market Cap £115.7m
Enterprise Value £45.9m
Revenue £n/a
Position in Universe 4720th / 6850
Unlock IFRX Revenue
Relative Strength (%)
1m -26.2%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -61.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 0.85 1.61
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, InflarxNV revenues was not reported. Net loss decreased 36% toEUR34M. Lower net loss reflects General and administrativeexpenses - Ba decrease of 90% to EUR939K (expense), Foreignexchange income increase of 8% to EUR3.7M (income), Otherexpenses decrease of 85% to EUR13K (expense). BasicEarnings per Share excluding Extraordinary Items increasedfrom -EUR2.05 to -EUR1.26.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


IFRX Revenue Unlock IFRX Revenue

Net Income

IFRX Net Income Unlock IFRX Revenue

Normalised EPS

IFRX Normalised EPS Unlock IFRX Revenue

PE Ratio Range

IFRX PE Ratio Range Unlock IFRX Revenue

Dividend Yield Range

IFRX Dividend Yield Range Unlock IFRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
IFRX EPS Forecasts Unlock IFRX Revenue
Profile Summary

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since November 16, 2017
No. of Shareholders: 4
No. of Employees: 49
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 43,228,415
Free Float (0.0%)
Eligible for
View larger map
Address Winzerlaer Str 2, JENA, 07745, Germany
Web https://www.inflarx.de/
Phone +49 3641 508180
Contact ()
Auditors Ernst & Young Wirtschaftsprufungsgesellschaft
IFRX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IFRX
Upcoming Events for IFRX
Wednesday 19th May, 2021 Estimate
Q1 2021 Inflarx NV Earnings Release
Wednesday 28th July, 2021 Estimate
Q2 2021 Inflarx NV Earnings Release
Frequently Asked Questions for Inflarx NV
What is the Inflarx NV share price?

As of 16/04/21, shares in Inflarx NV are trading at $3.7, giving the company a market capitalisation of £115.7m. This share price information is delayed by 15 minutes.

How has the Inflarx NV share price performed this year?

Shares in Inflarx NV are currently trading at $3.7 and the price has moved by -31.73% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Inflarx NV price has moved by -52.95% over the past year.

What are the analyst and broker recommendations for Inflarx NV?

Of the analysts with advisory recommendations for Inflarx NV, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Inflarx NV is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Inflarx NV next release its financial results?

Inflarx NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Inflarx NV dividend yield?

Inflarx NV does not currently pay a dividend.

Does Inflarx NV pay a dividend?

Inflarx NV does not currently pay a dividend.

When does Inflarx NV next pay dividends?

Inflarx NV does not currently pay a dividend.

How do I buy Inflarx NV shares?

To buy shares in Inflarx NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Inflarx NV?

Shares in Inflarx NV are currently trading at $3.7, giving the company a market capitalisation of £115.7m.

Where are Inflarx NV shares listed? Where are Inflarx NV shares listed?

Here are the trading details for Inflarx NV:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: IFRX
What kind of share is Inflarx NV?

Based on an overall assessment of its quality, value and momentum, Inflarx NV is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Inflarx NV share price forecast 2021?

Shares in Inflarx NV are currently priced at $3.7. At that level they are trading at 0.168% discount to the analyst consensus target price of 0.00.

Analysts covering Inflarx NV currently have a consensus Earnings Per Share (EPS) forecast of -0.834744221 for the next financial year.

How can I tell whether the Inflarx NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inflarx NV. Over the past six months, the relative strength of its shares against the market has been -39.68%. At the current price of $3.7, shares in Inflarx NV are trading at -20.99% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Inflarx NV PE Ratio?

We were not able to find PE ratio data for Inflarx NV.

Who are the key directors of Inflarx NV?

We were unable to find the directors for Inflarx NV.

Who are the major shareholders of Inflarx NV?

Here are the top five shareholders of Inflarx NV based on the size of their shareholding:

Suvretta Capital Management, LLC Hedge Fund
Percentage owned: 14.54% (6.29m shares)
Great Point Partners, LLC Hedge Fund
Percentage owned: 10.18% (4.40m shares)
Staidson Hong Kong Investment Co Ltd Corporation
Percentage owned: 5.36% (2.32m shares)
Guo (Renfeng M.D.) Individual Investor
Percentage owned: 4.04% (1.74m shares)
Riedemann (Niels C. M.D.) Individual Investor
Percentage owned: 2.47% (1.07m shares)
Similar to IFRX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.